FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to selenophene compound of formula (I) or its pharmaceutically acceptable salt. X stands for selenium, Y and Z stand for carbon atoms; or Y stands for selenium, X and Z stand for carbon atoms; or Z stands for selenium, X and Y stand for carbon atoms; A stands for N; B stands for NR5, where R5 is selected from hydrogen, or alkyl; Ar stands for aryl or heteroaryl ring; aryl represents benzene or naphthalene ring, and heteroaryl represents 6-membered aromatic ring, which contains one, two or three nitrogen atoms; or heteroaryl stands for 5-membered aromatic ring, which contains one or several heteroatoms, selected from sulphur, oxygen and nitrogen, on condition that not more than one oxygen or sulphur atom is present; and such rings include pyridine, pyridazine, pyrazine, pyrimidine, thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole and isothiazole; optionally substituted with one, two or several groups, independently selected from hydrogen, halogen, thiol, sulphonamide, C1-6alkyl, secondary C1-6alkyl, tertiary C1-6alkyl, C2-6alkinyl, C1-4alkoxycarbonyl and phenyl; R1, R2 and R3 are independently selected from hydrogen, carboxylic acid, amino, nitro, cyano, sulphonic acid, thiol, trihalomethyl, C1-6alkyl, secondary C1-6alkyl, tertiary C1-6alkyl, C1-4alkoxycarbonyl, aminocarbonyl, C1-6alkylaminocarbonyl, di(C1-6alkyl)aminocarbonyl, and phenyl; or R1 and R2 are bound, and together with atoms, which they are bound to, they form 5-7-membered optionally substituted carbocyclic or perhydroheterocyclic ring, given in invention formula; or R1 and R2 are bound, and together with atoms, which they are bound to, form optionally substituted aryl or non-substituted heteroaryl ring, fused with selenophene; and aryl represents benzene ring, and heteroaryl represents 6-membered aromatic ring, which contains one nitrogen atom. Methods of obtaining selenophene compound (versions), pharmaceutical composition, methods of treatment or inhibition, or control of cell proliferative disorder are also claimed.
EFFECT: invention makes it possible to obtain selenophene compound, which has anticancer activity.
29 cl, 2 tbl, 35 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO) PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | 2011 |
|
RU2597609C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
NEW INHIBITOR BASED ON A QUINOLINE DERIVATIVE | 2019 |
|
RU2802283C2 |
FGFR4 INHIBITORS | 2014 |
|
RU2715708C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
HETEROARYL COMPOUNDS AS IRAK TYPE II INHIBITORS AND THEIR USE | 2019 |
|
RU2810338C2 |
NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2585177C2 |
2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
Authors
Dates
2015-10-20—Published
2011-12-07—Filed